Trial Profile
A Randomized, Double Blinded Study of Actonel for the Prevention of Bone Loss in Patients Receiving High Dose Corticosteroids for the Treatment of Acute Lymphocytic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Risedronic acid (Primary) ; Calcium; Vitamin D
- Indications Corticosteroid-induced osteoporosis
- Focus Therapeutic Use
- 18 Dec 2013 Planned end date changed from 28 Feb 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
- 21 Aug 2013 Additional information source identified and integrated ClinicalTrials.gov record NCT00452439
- 21 Aug 2013 New trial record